NCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
Clinical Trials
9 trialsNCT07210775 2026-03-04
Topical Imiquimod Treatment of Oral Dysplasia
University of Southern California
Phase 1/2 Recruiting
NCT01795313 2026-02-05
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
University of Pittsburgh
Phase 1 Terminated
NCT02600949 2026-01-29
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
NCT04808245 2025-09-22
INTERCEPT-H3
German Cancer Research Center
Phase 1 Active not recruiting
NCT02059499 2025-07-23
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
AIDS Malignancy Consortium
Phase 3 Completed
NCT03196180 2025-04-08
Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Completed